Pub. Date : 1998 Apr 23
PMID : 9572490
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Treatment of cells with a proteasome inhibitor, such as ALLN or MG132, blocks EGF-mediated NF-kappaB activation, indicating that EGF-induced NF-kappa-B activation requires proteasome-dependent IkappaB degradation. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | epidermal growth factor | Mus musculus |
| 2 | Treatment of cells with a proteasome inhibitor, such as ALLN or MG132, blocks EGF-mediated NF-kappaB activation, indicating that EGF-induced NF-kappa-B activation requires proteasome-dependent IkappaB degradation. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | epidermal growth factor | Mus musculus |
| 3 | Treatment of cells with a proteasome inhibitor, such as ALLN or MG132, blocks EGF-mediated NF-kappaB activation, indicating that EGF-induced NF-kappa-B activation requires proteasome-dependent IkappaB degradation. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 | Mus musculus |